ReviewSeminars in oncology2016
Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma.
Review in Seminars in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- Hewei Jiangni recipe improved the quality of life in patients with cold-heat mixed nonerosive reflux disease: a randomized, double-blinded study.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Trial
- Preliminary insights into gut microbiome shifts as screening proxy for MASLD disease progression.Scientific reports · 2026Article
- Investigating the causal role of the gut microbiota in esophageal cancer and its subtypes: a two-sample Mendelian randomization study.BMC cancer · 2024Article
- From microbes to medicine: harnessing the power of the microbiome in esophageal cancer.Frontiers in immunology · 2024Review
- Review
- Immuno-oncology-microbiome axis of gastrointestinal malignancy.World journal of gastrointestinal oncology · 2023Review
- The Role of the Microbiota in Esophageal Cancer.Cancers · 2023Review
- Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease.Frontiers in cellular and infection microbiology · 2023Article
- Distinct microbiota dysbiosis in patients with laryngopharynx reflux disease compared to healthy controls.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022Article
- Characteristics of human oral microbiome and its non-invasive diagnostic value in chronic kidney disease.Bioscience reports · 2022Article
- Host-Microbiota Interactions in the Esophagus During Homeostasis and Allergic Inflammation.Gastroenterology · 2022Article
- Porphyromonas gingivalis promotes tumor progression in esophageal squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2021Article
- Gut Microbiota for Esophageal Cancer: Role in Carcinogenesis and Clinical Implications.Frontiers in oncology · 2021Review
- Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression.Frontiers in cell and developmental biology · 2021Review
- Effects ofFrontiers in cellular and infection microbiology · 2021Article
- Microbiome of the Aerodigestive Tract in Health and Esophageal Disease.Digestive diseases and sciences · 2021Review
- Influence of microbiota on immunity and immunotherapy for gastric and esophageal cancers.Gastroenterology report · 2020Review
- Linking gut microbiota with the human diseases.Bioinformation · 2020Article
- Microbiota of the Oropharynx and Endoscope Compared to the Esophagus.Scientific reports · 2019Article
- Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified.World journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Esophageal cancer is one of the deadliest cancers, with a dismal prognosis. It is increasingly recognized that esophageal cancer is a heterogeneous disease. It can be subdivided into two distinct groups: squamous cell carcinoma and adenocarcinoma, based on histological appearance. In the Western world, the incidence of squamous cell carcinoma was considerably higher than esophageal adenocarcinoma (EA) until the 1990s when, due to a dramatic increase, the incidence of EA surpassed that of squamous cell carcinoma. EA typically follows a well-established stepwise evolution from chronic inflammation due to reflux esophagitis (RE) that progresses to metaplasia (Barrett's esophagus [BE]) to dysplasia, which often culminates in EA. The pathophysiology of EA is complex and involves diverse factors, including gastroesophageal reflux, gastric acid secretion, dysfunction of the antireflux barrier, gastric emptying disturbances, and abnormalities in esophageal defense mechanisms. The current understanding of the etiology of EA is mainly derived from epidemiological studies of risk factors such as cigarette smoking, obesity, gastroesophageal reflux disorders (GERD), and low fruit and vegetable consumption. Numerous studies have been done, but the factors that drive the dynamic increase in the incidence of EA remain elusive. The advent of widespread antibiotic use occurred in the 1950s, preceding the surge of EA. Based on this temporal sequence, it has been hypothesized that antibiotics alter the microbiome to which the esophagus is exposed in patients who have GERD and that chronic exposure to this abnormal microbiome (ie, changes in species diversity or abundance) accounts for the increase in EA. If changes in the proposed factors alter the stepwise progression (RE-BE-dysplasia-EA), they may represent potential targets for chemoprevention. New discoveries will help improve our understanding of the biology and pathogenesis of these cancers, and aid in finding novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.